Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnostic Accuracy of CT for Evaluating Circumferential Resection Margin Status in Resectable or Borderline Resectable Pancreatic Head Cancer: A Prospective Study Using Axially Sliced Surgical Pathologic Correlation

  • Ji Hoon Park (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Yoo-Seok Yoon (Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Seungjae Lee (Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University) ;
  • Hae Young Kim (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Ho-Seong Han (Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Jun Suh Lee (Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Won Chang (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Haeryoung Kim (Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Hee Young Na (Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Seungyeob Han (Department of Medicine, Seoul National University College of Medicine) ;
  • Kyoung Ho Lee (Department of Radiology, Seoul National University Bundang Hospital)
  • Received : 2021.06.16
  • Accepted : 2021.10.07
  • Published : 2022.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: CT plays a central role in determining the resectability of pancreatic cancer, which directs the use of neoadjuvant therapy. This study aimed to assess the diagnostic accuracy of CT in predicting circumferential resection margin (CRM) involvement in patients with resectable or borderline resectable pancreatic head cancer. Materials and Methods: Seventy-seven patients who were scheduled for upfront surgery for resectable or borderline resectable pancreatic head cancer were prospectively enrolled, and 75 patients (38 male and 37 female; mean age ± standard deviation, 68 ± 11 years) were finally analyzed. The CRM status was evaluated separately for the superior mesenteric artery (SMA) and posterior and superior mesenteric vein/portal vein (SMV/PV) margins. Three independent radiologists reviewed the preoperative CT images and evaluated the resection margin status. The reference standard for CRM status was pathologic examination of pancreaticoduodenectomy specimens in an axial plane perpendicular to the axis of the second portion of the duodenum. The diagnostic accuracy of CT was assessed for overall CRM involvement, defined as involvement of the SMA or posterior margins (per-patient analysis), and involvement of each of the three resection margins (per-margin analysis). The data were pooled using a crossed random effects model. Results: Forty patients had pathologically confirmed overall CRM involvement in pancreatic cancer, while CRM involvement was not seen in 35 patients. For overall CRM involvement, the pooled sensitivity and specificity were 15% (95% confidence interval: 7%-49%) and 99% (96%-100%), respectively. For each of the resection margins, the pooled sensitivity and specificity were 14% (9%-54%) and 99% (38%-100%) for the SMA margin, 12% (8%-46%) and 99% (97%-100%) for the posterior margin; and 37% (29%-53%) and 96% (31%-100%) for the SMV/PV margin, respectively. Conclusion: CT showed very high specificity but low sensitivity in predicting pathological CRM involvement in pancreatic cancer.

Keywords

Acknowledgement

This research was supported by Seoul National University Bundang Hospital Research Fund (14-2014-037). Yoo-Seok Yoon received a research grant from Seoul National University Bundang Hospital.

References

  1. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013;24:2484-2492 
  2. Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 2014;21:1530-1537 
  3. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846; discussion 846-848 
  4. National Comprehensive Cancer Network. Pancreatic adenocarcinoma (Version 1.2021). Tri-kobe.org Web site. https://www2.tri-kobe.org/nccn/guideline/pancreas/english/pancreatic.pdf. Published October 23, 2020. Accessed August 23, 2021 
  5. Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 2017;35:515-522 
  6. Blair AB, Sorber R, Rozich NS, Burkhart RA. A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. Pancreas 2019;48:973-984 
  7. Tamburrino D, Riviere D, Yaghoobi M, Davidson BR, Gurusamy KS. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2016;9:CD011515 
  8. Royal College of Pathologists. Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma. London: Royal College of Pathologists, 2002 
  9. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008;15:1651-1660 
  10. Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel) 2010;2:2001-2010 
  11. Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 2009;11:282-289 
  12. Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: making a case for standardized reporting of the resection margin using certified cancer center data. PLoS One 2021;16:e0248633 
  13. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery 2012;152:S103-S111 
  14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015;277:826-832 
  15. Verbeke CS. Resection margins and R1 rates in pancreatic cancer--are we there yet? Histopathology 2008;52:787-796 
  16. Mochizuki K, Gabata T, Kozaka K, Hattori Y, Zen Y, Kitagawa H, et al. MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma: correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol 2010;20:1757-1767 
  17. Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 2009;55:277-283 
  18. American Joint Committee on Cancer. AJCC cancer staging manual, 8th ed. New York: Springer International Publishing, 2017 
  19. Joo I, Lee JM, Lee ES, Son JY, Lee DH, Ahn SJ, et al. Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement. Radiology 2019;293:343-349 
  20. Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM, et al. Pancreatic cancer CT: prediction of resectability according to NCCN criteria. Radiology 2018;289:710-718 
  21. Deshmukh SD, Willmann JK, Jeffrey RB. Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 2010;194:668-674 
  22. Sai M, Mori H, Kiyonaga M, Kosen K, Yamada Y, Matsumoto S. Peripancreatic lymphatic invasion by pancreatic carcinoma: evaluation with multi-detector row CT. Abdom Imaging 2010;35:154-162 
  23. Verbeke CS, Knapp J, Gladhaug IP. Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology 2011;59:1111-1121 
  24. Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M, et al. Does size matter in pancreatic cancer? Reappraisal of tumour dimension as a predictor of outcome beyond the TNM. Ann Surg 2017;266:142-148 
  25. Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011;80:1383-1390 
  26. Inoue Y, Saiura A, Oba A, Kawakatsu S, Ono Y, Sato T, et al. Optimal extent of superior mesenteric artery dissection during pancreaticoduodenectomy for pancreatic cancer: balancing surgical and oncological safety. J Gastrointest Surg 2019;23:1373-1383 
  27. Okano K, Suto H, Oshima M, Maeda E, Yamamoto N, Kakinoki K, et al. A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 2017;24:2777-2784 
  28. Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol 2014;113:41-46 
  29. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011;11:346 
  30. Labori KJ, Lassen K, Hoem D, Gronbech JE, Soreide JA, Mortensen K, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017;17:94 
  31. Chawla A, Roland C, Ferrone C. ALLIANCE A021806 examines perioperative vs. adjuvant chemotherapy for resectable pancreatic cancer. In: American College of Surgeons, ed. The bulletin of the American College of Surgeons. Chicago: American College of Surgeons, 2020:40-43